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Summary
Chromosomal translocations affecting Mixed Lineage Leukemia gene (MLL) result in acute 
leukemias resistant to therapy. The leukemogenic activity of MLL fusion proteins is dependent on 
their interaction with menin, providing basis for therapeutic intervention. Here we report 
development of highly potent and orally bioavailable small molecule inhibitors of the menin-MLL 
interaction, MI-463 and MI-503, show their profound effects in MLL leukemia cells and 
substantial survival benefit in mouse models of MLL leukemia. Finally, we demonstrate efficacy 
of these compounds in primary samples derived from MLL leukemia patients. Overall, we 
demonstrate that pharmacologic inhibition of the menin-MLL interaction represents an effective 
treatment for MLL leukemias in vivo and provide advanced molecular scaffold for clinical lead 
identification.
Introduction
Acute leukemias represent a paradigm for understanding how genetic and epigenetic 
modifications lead to tumorigenesis (Figueroa et al., 2010; Rodriguez-Paredes and Esteller, 
2011). Despite the complexity of these alterations, which represent a challenge in 
developing targeted therapies, numerous efforts have been focused on developing effective 
agents for acute leukemias (Daigle et al., 2011; Dawson et al., 2011; Peloquin et al., 2013; 
Zuber et al., 2011). Acute leukemias with translocations of the Mixed Lineage Leukemia 
gene (MLL), which constitute about 5–10% of acute leukemias in adults (Marschalek, 2011) 
and ~70% of acute leukemias in infants (Tomizawa et al., 2007), still represent mostly 
incurable diseases (Dimartino and Cleary, 1999; Marschalek, 2011). Fusion of MLL with 
one out of over 60 partner genes leads to expression of chimeric MLL fusion proteins, all of 
which retain an approximately 1,400 amino acids N-terminal fragment of MLL fused with 
the fusion partner (Hess, 2004; Krivtsov and Armstrong, 2007; Slany, 2009). Expression of 
MLL fusion proteins enhances proliferation and blocks differentiation of hematopoietic 
cells, ultimately leading to acute leukemia (Slany, 2005). Patients with MLL leukemias 
respond poorly to currently available treatments (Slany, 2005), with only about 35% 5-year 
overall survival rate (Dimartino and Cleary, 1999), emphasizing the urgent need for 
development of more effective therapies.
The MLL fusion proteins interact with menin, a protein that binds to the N-terminal 
fragment of MLL retained in all MLL fusion proteins (Caslini et al., 2007; Grembecka et al., 
2010; Yokoyama and Cleary, 2008; Yokoyama et al., 2005). Numerous studies 
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demonstrated a critical role of menin as an oncogenic cofactor in leukemic transformations 
mediated by MLL fusion proteins (Caslini et al., 2007; Yokoyama and Cleary, 2008; 
Yokoyama et al., 2005). Menin is a highly specific and direct binding partner of MLL and 
MLL fusion proteins that is required for regulation of their target genes (Yokoyama et al., 
2005). Genetic disruption of the menin-MLL fusion protein interaction abrogates oncogenic 
properties of MLL fusion proteins and blocks development of acute leukemia in vivo 
(Yokoyama et al., 2005). These data, together with the evidence that menin is not a requisite 
cofactor of MLL1 during normal hematopoiesis (Li et al., 2013), validate the menin-MLL 
interaction as an attractive therapeutic target to develop targeted drugs for MLL leukemia 
patients.
Despite the critical role of menin in leukemogenesis mediated by MLL fusion proteins, it 
remains unknown whether pharmacological inhibition of the menin-MLL interaction can 
suppress development of acute leukemia in vivo and whether it would affect normal 
hematopoiesis. We previously reported first-generation small molecule inhibitors of the 
menin-MLL interaction (Grembecka et al., 2012; He et al., 2014; Shi et al., 2012), which 
represent valuable tool compounds, but are not suitable for in vivo studies due to moderate 
cellular activity and poor pharmacological properties. The goal of this study was to develop 
highly potent small molecule inhibitors of the menin-MLL interaction with appropriate 
pharmacokinetic profile and to determine whether small molecule inhibition of the menin-
MLL interaction can represent a valid therapeutic approach for acute leukemias associated 
with MLL rearrangements.
Results
Structure-based development of potent menin-MLL inhibitors
To develop menin-MLL inhibitors with favorable drug-like properties suitable for in vivo 
efficacy studies, we employed structure-based design and very substantially reengineered 
our previously reported compounds represented by the most potent MI-2-2, Figure S1A, 
(Grembecka et al., 2012; Shi et al., 2012). Although MI-2-2 represents a useful chemical 
tool, it is not suitable for in vivo efficacy studies due to modest cellular activity and very 
poor metabolic stability (Figure S1A–C). Using the crystal structure of the menin-MI-2-2 
complex (Shi et al., 2012) we employed structure-based design combined with medicinal 
chemistry efforts, resulting in development of menin-MLL inhibitors with modified 
molecular scaffold (Table S1). These efforts led to identification of MI-136 (Figure 1A), 
which was developed by introducing the cyano-indole ring connected to the 
thienopyrimidine core via a piperidine linker (Table S1). MI-136 demonstrates potent 
inhibitory activity and strong binding affinity to menin (Figure 1A), providing an excellent 
molecular scaffold for further modifications. Based on the binding mode of MI-136 to 
menin (Figure S1D), we explored three substitution sites on the indole ring of MI-136 (R1, 
R2 and R3, Figure 1B) to further improve potency and drug-like properties by optimizing 
hydrophobic contacts (at R2) or polar interactions (at R1 and R3) (Table S2). The molecular 
determinants for recognition of MI-136 analogues in the MLL binding site on menin are 
summarized in Figure 1B. Our medicinal chemistry efforts resulted in identification of two 
lead compounds: MI-463 and MI-503, which were obtained by combining two (MI-463) or 
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three (MI-503) best substituents on the indole ring (Figure 1C, Table S2). MI-503 and 
MI-463 are the most potent inhibitors we developed, both bind to menin with low nanomolar 
binding affinities, and demonstrate very potent inhibition of the menin-MLL interaction 
(Figure 1C, 1D and Figure S1E). Crystal structure validates binding of MI-503 to the MLL 
site on menin (Figure 1E, Table S3). MI-503 occupies the F9 and P13 pockets on menin, 
forming a hydrogen bond with Tyr276, and also extends beyond the P13 pocket to form 
hydrogen bonds with Trp341 and Glu366 (Figure 1E). In addition to strong in vitro potency, 
MI-463 and MI-503 have very favorable drug-like properties, including metabolic stability 
(Figure S1C) and pharmacokinetic profile in mice (see below), which makes them very 
attractive candidates to evaluate the therapeutic potential of menin-MLL inhibitors in vivo.
MI-503 and MI-463 demonstrate selective and on-target activity in MLL leukemia cells
We performed a detailed characterization of MI-463 and MI-503 in MLL leukemia cells to 
assess their activity, selectivity and validate the mechanism of action. First, we found that 
both compounds can reach the target protein in mammalian cells and effectively inhibit the 
menin-MLL-AF9 interaction at sub-micromolar concentrations, as assessed in the co-
immunoprecipitation experiment (Figure 2A). Treatment of murine bone marrow cells 
(BMC) transformed with the MLL-AF9 oncogene with MI-463 and MI-503 resulted in 
substantial growth inhibition, with half-maximal growth inhibitory concentration (GI50) 
values of 0.23 μM and 0.22 μM, respectively, measured after 7 days of treatment (Figure 
2B). The cell growth inhibitory effect of MI-503 was time-dependent, with a pronounced 
effect achieved after 7–10 days of treatment (Figure S2A), which is similar to other small 
molecule inhibitors of epigenetic targets, including DOT1L (Bernt et al., 2011) and EZH2 
(Knutson et al., 2012). MI-463 and MI-503 were selective towards MLL-AF9 BMCs as no 
effect on cell growth inhibition was observed in BMCs transformed with the Hoxa9/Meis1 
oncogenes (HM-2, Figure 2B). Similarly, we observed pronounced growth suppressive 
activity of MI-503 and MI-463 in a panel of human MLL leukemia cell lines (GI50 at 250 
nM – 570 nM range for MI-503), but only a minimal effect in human leukemia cell lines 
without MLL translocations (Figure 2C and Figure S2B). Selective killing of MLL leukemia 
cells is attributed to inhibition of the menin-MLL interaction as the close analogs MI-372 
and MI-405, which are much weaker menin-MLL inhibitors (IC50 = 0.92 μM and 15.6 μM, 
respectively), did not show growth suppressive effects in MLL leukemia cells (Figure S2C–
S2F).
MI-503 and MI-463 were also very effective in inducing differentiation of MLL leukemia 
cells, as reflected by pronounced phenotypic changes from primitive blasts to more mature 
myeloid cells, and substantially increased expression of CD11b, a myeloid differentiation 
marker (Figure 2D–2F and Figure S2G–S2I). These effects were accompanied by reduced c-
kit (CD117) expression, a marker associated with leukemia stem cells (LSCs) (Krivtsov et 
al., 2006; Somervaille and Cleary, 2006) (Figure S2J–S2K). Interestingly, effects on 
apoptosis were less pronounced as higher concentrations of both compounds were required 
for pronounced apoptotic effect in MLL leukemia cells (Figure 2G). Treatment with sub-
micromolar concentrations of MI-503 and MI-463 also led to markedly reduced expression 
of Hoxa9 and Meis1, downstream targets of MLL fusion proteins substantially upregulated 
in MLL leukemias (Figure 2H). Overall, we developed very potent menin-MLL inhibitors, 
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which selectively block proliferation of MLL leukemia cells through a specific, on-target 
mechanism of action, representing very promising candidates for in vivo studies.
To assess the effect of a long-term treatment combined with compound withdrawal we 
treated MV4;11 human leukemia cells expressing MLL-AF4 with MI-503 followed by the 
wash-out phase to eliminate the compound and subsequent resupply with MI-503, with each 
phase continuing for 10 days (Figure 2I and Figure S2L). To avoid cell death, MI-503 was 
used at 0.2 – 0.6 μM concentrations that inhibit proliferation but do not induce high level 
apoptosis. As expected, MI-503 induced marked anti-proliferative effects in the first 
treatment phase, with a GI50 value of 200 nM at day 10 (Figure 2I). Withdrawal of MI-503 
restored proliferation of MV4;11 cells; however, this effect was concentration-dependent, 
and less pronounced recovery was observed for cells treated with the highest MI-503 
concentration (Figure 2I). Restoration of MI-503 treatment at day 21 resulted in further 
inhibition of MV4;11 cell proliferation (Figure 2I and Figure S2L). Interestingly, upon 
prolonged treatment with 0.6 μM of MI-503 the MV4;11 cells began exhausting their 
proliferative potential (Figure S2L, bottom panel). Furthermore, expression of HOXA9 and 
MEIS1 was markedly reduced at the end of each treatment phase (days 10 and 30), (Figure 
2J). In contrast, expression of HOXA9 and MEIS1 was restored to the DMSO control level at 
the end of the wash-out phase (day 20), (Figure 2J). These data support the need for 
continuous inhibition of menin to block the activity of MLL fusion oncogenes. The ability to 
suppress proliferation of MV4;11 cells using prolonged treatment with MI-503 suggests that 
resistance did not develop over the duration of the experiment.
Menin-MLL inhibitors reverse gene expression signatures associated with MLL-rearranged 
leukemia cells
To assess the effects of menin-MLL inhibitors on global gene expression in the MLL-
rearranged leukemias, we performed gene expression studies in MV4;11 human leukemia 
cells (expressing MLL-AF4) after treatment with the MI-389 menin-MLL inhibitor, a close 
analog of MI-503 with a similar in vitro and cellular activity (Figure S3A–S3B). Significant 
changes in gene expression were found for 478 and 477 genes up- and downregulated, 
respectively (Table S4). Gene set enrichment analysis (GSEA) demonstrated strong 
downregulation of genes identified as downstream targets of MLL-AF4 (Guenther et al., 
2008) and MLL-AF9 (Bernt et al., 2011) following treatment with MI-389 (Figure 3A, 3B). 
These included multiple genes implicated in MLL fusion protein mediated leukemogenesis, 
such as homeobox genes (HOXA9, HOXA10, MEIS1, PBX3), FLT3 and other downstream 
targets of MLL fusion proteins (MEF2C, BCL2 and CDK6) (Figure 3A, 3B and Table S4). 
Downregulated expression of these genes was consistent with phenotypic consequences of 
treatment with the menin-MLL inhibitor (Figure S3C). GSEA also revealed a global 
upregulation of genes underexpressed in leukemia stem cells (CD34+ CD38− progenitor 
cells) (Gal et al., 2006) and in primitive hematopoietic progenitor cells (Jaatinen et al., 
2006), including genes associated with differentiation (ITGAM, which encodes the cell 
surface marker CD11b associated with myeloid differentiation, and MNDA), following 
MI-389 treatment, Figure 3C.
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We have further used qRT-PCR to validate expression changes for selected genes in 
MV4;11 and MOLM-13 (expressing MLL-AF9) human leukemia cell lines upon treatment 
with MI-389 and MI-503 (Figure 3D, 3E). We observed markedly downregulated expression 
of Homeobox genes (HOXA9, HOXA10, HOXA7, PBX3, MEIS1) and other downstream 
targets of MLL fusion proteins (DLX2, MEF2C, FLT3) and up-regulation of MNDA, a 
differentiation marker of myeloid cells (Figure 3D, 3E), consistent with the gene expression 
data from the microarray studies in MV4;11 cells (Figure 3A, 3B). Overall, these results 
demonstrate that pharmacologic inhibition of the menin-MLL interaction reverses the gene 
expression signature in MLL-rearranged leukemia cells, providing an attractive strategy to 
reprogram these cells towards differentiation.
Menin-MLL inhibitors block hematologic tumors in vivo and reduce MLL leukemia tumor 
burden
We next aimed to establish the therapeutic potential of menin-MLL inhibitors in vivo using 
mouse models of MLL leukemia. First, we characterized the pharmacokinetic (PK) 
properties of MI-503 and MI-463 in mice. Both compounds achieved high level in 
peripheral blood following a single intravenous or oral dose, while also showing high oral 
bioavailability (~45% for MI-463 and 75% for MI-503), Figure 4A and Figure S4A. We 
then assessed the effect of MI-463 and MI-503 on in vivo tumor growth in mouse xenograft 
model utilizing MV4;11 human MLL leukemia cells implanted into BALB/c nude mice. 
Both MI-463 and MI-503 induced strong inhibition of tumor growth with once daily 
intraperitoneal (i.p.) administration, albeit MI-503 showed more pronounced effects (Figure 
4B). Treatment with MI-503 resulted in an over 80% reduction in MV4;11 tumor volume 
and complete tumor regression in two mice. Pronounced tumor growth inhibition correlated 
well with the level of both compounds in the tumor samples (Figure S4B). Importantly, 
prolonged treatment (38 days) with MI-503 induced no toxicity in mice as reflected by no 
alterations in the body weight and no morphological changes in liver and kidney tissues 
(Figure S4C, S4D). Furthermore, gene expression studies performed in samples isolated 
from the MV4;11 tumors revealed significant reduction in expression of MLL fusion protein 
target genes, HOXA9 and MEIS1, upon treatment with MI-503 and MI-463 (Figure 4C). 
Taken together, the reduction in tumor growth correlated with a decrease in expression of 
MLL-fusion target genes in vivo, validating on-target activities of MI-463 and MI-503.
We then assessed the effect of MI-503 and MI-463 in disseminated human MLL-AF4 
leukemia using a xenotransplantation model. MV4;11 cells expressing luciferase were 
injected into NSGS or NSG mice via tail vein and treatment was initiated 5 days later to 
allow for efficient engraftment of leukemic cells. Leukemia progression was monitored by 
bioluminescence imaging. Based on the pharmacokinetic profiles, we selected twice-daily 
treatment regimen to sustain a therapeutic concentration of the compounds in the blood. Ten 
consecutive days of treatment with MI-503 resulted in a marked delay in progression of 
MLL leukemia in mice and significantly reduced leukemia tumor burden (Figure 4D and 
Figure S4E). Similarly, 20 days treatment of MV4;11 xenograft recipient mice with MI-463 
also resulted in a substantial delay in leukemia progression as manifested by a marked 
decrease in the bioluminescence level measured over the course of the experiment (Figure 
4E, 4F). Reduced bioluminescence was associated with a significant decrease in the 
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population of leukemic cells in the peripheral blood, spleen and bone marrow samples 
harvested from mice treated with MI-463 (Figure 4G). Furthermore, we observed reduced 
expression of MLL fusion target genes (HOXA9, MEIS1, MEF2C) and increase in the 
expression level of ITGAM upon treatment of mice with MI-463 (Figure 4H). Collectively, 
these findings demonstrate that MI-503 and MI-463 have a potent anti-leukemic effect in 
vivo when applied as single agents. Importantly, these data suggest that resistance did not 
emerge after prolonged (20 days) treatment with MI-463.
Menin-MLL inhibitors substantially improve survival of MLL leukemic mice
We next assessed the effects of menin-MLL inhibitors on survival of MLL leukemia mice, 
using a bone marrow transplantation model of murine MLL-AF9 leukemia (Figure S5A). 
Despite short latency time in this aggressive leukemia model (~15 days) we initiated 
treatment five days after transplantation to test efficacy of menin-MLL inhibitors in the 
established disease model. MI-463 at 50 mg/kg and MI-503 at 80 mg/kg were administered 
twice daily by oral gavage for ten consecutive days. The presence of abundant blasts in the 
peripheral blood, bone marrow and spleen was used to validate terminal leukemia in mice 
(Figure S5B). Importantly, treatment with either compound strongly delayed leukemia 
progression as reflected by a substantial survival benefit in MLL-AF9 leukemia mice when 
MI-463 and MI-503 were applied as single agents (Figure 5A). The median survival of 
MLL-AF9 leukemia mice was increased by ~70% and ~45% upon treatment with MI-463 
and MI-503, respectively (Figure 5A), demonstrating their pronounced effects in blocking 
MLL leukemia progression in vivo.
To further validate that treatment with menin-MLL inhibitors delayed leukemia progression, 
we additionally tested the MI-463 compound in the MLL-AF9 leukemia model using the 
same treatment regimen as in survival experiment (Figure 5A). Following 10 days of 
treatment all animals were sacrificed and extensive analysis of leukemia progression was 
performed in vehicle and compound treated cohorts with samples collected at the same time 
point. We observed notably reduced spleen size and weight (Figure 5B and 5C) and 
substantially decreased level of blasts in bone marrow samples upon treatment with MI-463 
versus vehicle control (Figure 5D and 5E). These effects were accompanied by substantially 
reduced blast infiltration of the liver and spleen upon treatment with MI-463 (Figure 5F and 
Figure S5C). The bone marrow samples isolated from mice treated with MI-463 showed a 
sub-population of cells with a differentiated phenotype as manifested by the appearance of 
cells with a neutrophil-like morphology (Figure 5G). The white blood cell count was 
decreased in the peripheral blood of the MLL-AF9 mice upon treatment with MI-463, while 
other blood cells and blood parameters were not affected (Figure 5H and Figure S5D). 
MI-463 administration was well tolerated, and no significant body weight loss was observed 
(Figure S5E). Furthermore, treatment of mice with MI-463 resulted in a marked reduction in 
the expression level of MLL-fusion downstream targets, Hox9, Meis1, Mef2c and Flt3, as 
well as a substantial increase in the expression level of Itgam differentiation marker in the 
bone marrow samples (Figure 5I). Taken together, these data demonstrate that 
pharmacologic inhibition of the menin-MLL interaction substantially delays progression of 
MLL leukemia in vivo in murine models through on-target activity without causing toxicity.
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Menin-MLL inhibitors do not impair normal hematopoiesis in vivo
Given the role of MLL1 in normal hematopoiesis (Ernst et al., 2002; McMahon et al., 2007), 
we assessed whether pharmacological inhibition of the menin-MLL interaction affects the 
normal hematopoiesis in mice. C57BL/6 mice were treated with efficacious doses of MI-463 
and MI-503 for 10 days using the same treatment regimen as in survival experiments (Figure 
5A). Importantly, no decrease in body weight, organ weight or tissue damage was observed 
upon treatment with either compound (Figure S6A–S6C). We then performed detailed 
analysis of bone marrow samples and found that bone marrow cellularity was preserved 
upon treatment with MI-463 and MI-503 (Figure 6A). Flow cytometric analysis showed that 
bone marrow cell populations highly enriched for hematopoietic stem cells were not 
decreased upon treatment with menin-MLL inhibitors (LSK progenitors defined as 
Lin−Sca-1+c-Kit+ and long-term hematopoietic stem cells defined as LSK CD48−CD150+) 
(Figure 6B). In fact these populations were even slightly increased upon treatment. Analysis 
of mature myeloid cells (CD11b+Gr-1+) showed no impact in the inhibitor-treated mice 
(Figure 6C). Phenotypic analysis of B cell populations showed a mild increase in pro-B cell 
numbers and no effect on other B cells populations upon treatment with MI-463 and MI-503 
(Figure 6D and Figure S6D). Gene expression analysis performed in LSK progenitors 
showed no reduction in the expression level of the menin and/or MLL dependent genes, 
including Hoxa9 and Meis1, upon treatment of mice with MI-463 or MI-503 (Figure 6E and 
Figure S6E). This is consistent with the modest effect on expression of these genes reported 
in LSKs after genetic loss of Men1 encoding menin (Artinger et al., 2013; Li et al., 2013; 
Maillard et al., 2009). These results suggest that the MLL-rearranged cells are more 
sensitive to the treatment with the menin-MLL inhibitors than normal LSKs, supporting the 
existence of a therapeutic window for these compounds.
We have also assessed the effect of MI-503 on normal hematopoiesis after prolonged 
treatment of mice (38 days of continued treatment with efficacious doses of MI-503) using 
the xenograft MV4;11 model described above (Figure 4B). No significant effect on bone 
marrow cellularity, Lin−c-Kit+ progenitors and long-term hematopoietic stem cells was 
observed (Figure 6F–6G), with a slight increase in mature myeloid cells in bone marrow 
(Figure 6F). Overall, these findings show that pharmacologic inhibition of the menin-MLL 
interaction dose not negatively affect normal hematopoiesis, which rules out a potential “on-
target” toxicity of the menin-MLL inhibitors. Importantly, our results are in agreement with 
recent studies suggesting that menin is not a requisite cofactor of MLL1 during normal 
hematopoiesis (Li et al., 2013; Maillard and Hess, 2009).
Menin-MLL inhibitors selectively kill MLL leukemia primary patient samples
To evaluate therapeutic potential of menin-MLL inhibitors we studied the effects of MI-503 
and MI-463 on primary samples isolated from MLL leukemia patients as well as in several 
AML patient samples without MLL translocation (Figure S7A, S7B). Both compounds 
substantially reduced clonogenic efficiency in all MLL leukemia patient samples, with over 
50% reduction in colony number at submicromolar or low micromolar concentrations 
(Figure 7A). Notably, the morphology and size of colonies changed upon treatment with 
menin-MLL inhibitors, resulting in significantly smaller and more diffuse colonies when 
compared to DMSO treated samples (Figure 7C). In contrast, both compounds had little 
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effect on colony formation in control AML patient samples, except at the highest 
concentration (6 μM) in the AML-9571 sample (Figure 7B and 7C).
We also assessed the effect of MI-463 in an additional set of AML patient samples and 
observed a marked decrease in cell growth and blast population in MLL leukemia patient 
samples but not in primary AML samples without MLL translocations (Figure 7D, 7E and 
Figure S7C–S7D). Furthermore, increased cell size was observed following treatment with 
MI-463 specifically in primary MLL leukemia cells but not in other AML samples (Figure 
7E), suggesting differentiation of these cells, although this effect needs further investigation. 
No effect on growth and blast population in the primary MLL patient samples was detected 
for MI-372 negative control compound (Figure S7C–S7E). Taken together, these data 
provide compelling evidence supporting the therapeutic potential of menin-MLL inhibitors 
in MLL leukemias.
Discussion
Acute leukemias with MLL rearrangements represent an unmet medical need as therapeutic 
agents have not been developed for clinical use in MLL leukemia patients. Menin plays a 
critical role as an oncogenic co-factor of MLL fusion proteins in leukemia (Yokoyama et al., 
2005). Based on genetic data, inhibition of the menin-MLL interaction was proposed as a 
potential therapeutic approach (Li et al., 2013; Yokoyama et al., 2005), but this strategy has 
not been validated with pharmacologic agents. Here, we demonstrate that pharmacologic 
inhibition of the menin-MLL interaction with small molecules blocks progression of MLL 
leukemia in vivo without impairing normal hematopoiesis. These effects were achieved with 
small molecule inhibitors MI-463 and MI-503 that directly bind to menin with low 
nanomolar binding affinities and effectively block the menin-MLL interaction. Both 
compounds have appropriate pharmacokinetic profile and high oral bioavailability and their 
in vivo administration results in a substantial extension of survival in a mouse model of 
MLL leukemia through on-target mechanism of action. Importantly, these compounds do 
not impair normal hematopoiesis in mice, providing evidence that a sufficient therapeutic 
window can be achieved. Overall, this study supports clinical applications of menin-MLL 
inhibitors as targeted therapeutics against MLL-rearranged leukemias.
Based on our studies, MI-463 and MI-503 are two lead compounds with comparable 
efficacy and drug-like properties. MI-503 has better oral bioavailability and can be tolerated 
at higher doses in mice, but at this point we cannot distinguish which compound might 
represent a better candidate for further development as targeted therapy for the treatment of 
patients suffering from MLL leukemia. Follow-up studies, including pharmacological 
formulation, pharmacokinetic studies and long term toxicity in other species, including rats 
and dogs, are required to address this question. In case any potential undesired side effects 
emerge, additional substitutions on the indole ring of MI-463 or MI-503 could be explored 
to modulate these properties.
In this study we provide an example of targeted drug discovery where the oncogenic effects 
of genetic alterations can be reversed by effective blocking of a protein-protein interaction 
critical for oncogenesis. This approach represents an attractive strategy to develop therapies, 
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as protein-protein interactions typically show a high level of evolutionary conservation and 
functional mutations leading to drug resistance are far less likely to occur than in enzymes. 
These considerations, together with the results of our studies, validate that in vivo 
pharmacological inhibition of the menin-MLL fusion protein interaction offers a promising 
therapeutic opportunity for acute leukemias with MLL rearrangements. Recent reports 
emphasize oncogenic role of menin in other cancers, including hepatocellular carcinomas 
(Xu et al., 2013), raising a possibility that pharmacologic inhibition of this protein-protein 
interaction might have broader therapeutic applications in oncology, both for hematologic 
malignancies and solid tumors. The two compounds we report here may represent clinical 
lead candidates or provide an advanced molecular scaffold for further optimization into 
clinical lead compounds.
Experimental Procedures
Chemistry
Chemical synthesis and chemical characterization of compounds are provided in the 
Supplemental Experimental Procedures.
Biochemical, biophysical and structural characterization of menin-MLL inhibitors
Inhibition of the menin-MLL interaction by small molecules was assessed by fluorescence 
polarization (FP) assay using the protocol described previously (Grembecka et al., 2010; 
Grembecka et al., 2012). Binding affinity of compounds (MI-136, MI-389, MI-463 and 
MI-503) to menin was assessed using Isothermal Titration Calorimetry experiments 
performed at 25 °C with compounds (50 μM – 100 μM) injected into menin (5 μM – 10 μM) 
in 10 μl aliquots. For co-crystallization experiments 2.5 mg/mL menin was incubated with 
small molecule inhibitors (MI-136 or MI-503) at 1:3 molar ratio. Crystals were obtained 
using the sitting drop technique at 10 °C by applying the procedure described previously 
(Shi et al., 2012). More details can be obtained in Supplemental Experimental Procedures.
Viability assays, cell differentiation and gene expression studies
For viability assays, leukemia cells were plated at relevant concentrations and treated with 
compounds or 0.25% DMSO and cultured at 37 °C for 7 days. Media was changed at day 4, 
viable cell numbers were restored to the original concentration and compounds were re-
supplied. MTT cell proliferation assay kit (Roche) was then employed, and plates were read 
for absorbance at 570 nm using a PHERAstar BMG microplate reader. Effect of menin-
MLL inhibitors on expression level was assessed by Real-time quantitative PCR (qRT-PCR) 
after 6 days of incubation of compounds with cells, with media changed and compound re-
supply at day 3. For cell differentiation studies, leukemia cells were treated with menin-
MLL inhibitors for 7 days, then harvested, washed and incubated with Pacific Blue rat anti-
mouse CD11b antibody (BD BioLegend, cat # 101224) before being analyzed by flow 
cytometry. More details can be obtained in Supplemental Experimental Procedures.
Efficacy studies in mice
All animal experiments were approved by the University of Michigan Committee on Use 
and Care of Animals and Unit for Laboratory Animal Medicine (ULAM). For efficacy 
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studies in MV4;11 subcutaneous xenograft mice model, 5 × 106 cells were injected into the 
4–6 week old female BALB/c nude mice. Treatment was started when the tumor size 
reached ~100 mm3. Vehicle (25% DMSO, 25% PEG400, 50% PBS) or compounds (MI-463 
or MI-503) were administrated once daily at designated doses using i.p. injections. For mice 
efficacy studies in bioimaging MV4;11 xenograft model, 6 to 8-week-old female NSGS or 
NSG mice were intravenously injected with 1 × 107 or 0.5 × 107 luciferase-expressing 
MV4;11 cells. At day 5, treatment with compound of vehicle was initiated and continued for 
10–20 consecutive days. To generate the MLL-AF9 leukemic mice, C57BL/6 female mice 
were transplanted with 1 × 105 spleen or bone marrow cells isolated from the primary 
recipient mice. Five days post-transplantation treatment with MI-463, MI-503 or vehicle was 
initiated and continued for 10 days. Mice were sacrificed upon signs of disease. Leukemia 
was confirmed by flow cytometric analysis of GFP+ cells as a surrogate for MLL-AF9 
expression. More details can be obtained in Supplemental Experimental Procedures.
Analysis of normal hematopoiesis in mice
Normal hematopoiesis was studies in C57BL/6 mice after 10 days of treatment with MI-463, 
MI-503 or vehicle control and in the BALB/c nude mice after 38 days of treatment with 
MI-503. See Supplemental Experimental Procedures for more details.
Primary patient samples
Patient-derived AML samples were collected in accordance with the guidelines and approval 
of institutional review boards at University of Pennsylvania Hospital, Weill Cornell Medical 
College, New York Presbyterian Hospital, and University of Michigan Hospital, and 
informed consent of each patient. Peripheral blood samples were collected and processed to 
isolate mononuclear cells using density gradient centrifugation and red blood cell lysis. Cells 
were frozen in 10% DMSO until used in experiments.
Clonogenic assay in methylcellulose with primary patient samples
Primary patient samples were grown in RPMI-1640 media (Lifetechnologies), supplemented 
with 10% FBS and 1% penicillin/streptomycin, in the presence of 10 ng/mL human IL-3, 10 
ng/mL IL-6 and 50 ng/m LSCF (PeproTech). 24 hr later, cells were plated in duplicates on 
methylcellulose media supplemented with human cytokines (Methocult H4435, StemCell 
Technologies) with cell density of 7.5–15 × 104 cells. Compounds or DMSO were added to 
the methylcellulose and incubated at 37 °C, 5% CO2 for 14 days at which time colonies 
were stained with iodonitrotetrazolium chloride and counted.
Cell viability assay in primary patient samples
Primary AML samples were treated with the compounds or vehicle (0.25% DMSO) for 7 
days. Cells were collected and stained with mouse anti-human CD45-APC-H7 (BD 
Bioscience), CD34-APC and CD38-PE-Cy7 (eBiosciences) prior to Annexin V (BD 
Bioscience) and 7-AAD (Life Technologies) staining. Cells were then analyzed using an 
LSR II flow cytometer (BD Bioscience) collecting at least 2 × 105 events for each sample. 
Data analysis was performed using FlowJo 9.3.2 software for Mac OS X (TreeStar). 
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Annexin V and 7-AAD double negative cells were scored as viable, and the viability was 
represented as the percent relative to DMSO treated cells.
Statistical analysis
Student’s t-test (unpaired, two-tailed) was used to calculate significance level between 
treatment groups in all experiments besides survival curves, where Log-rank (Mantel-Cox) 
test was applied to calculate p values. P values of less than 0.05 were considered significant. 
Graph generation and statistical analysis were performed using GraphPad Prism version 
6.02 software (GraphPad, La Jolla, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
Chromosomal translocations of MLL occur in aggressive acute leukemias affecting both 
children and adults. MLL fusion proteins require menin for leukemogenic activity, and 
selective targeting of the menin-MLL interaction represents a potential therapeutic 
approach for acute leukemias with MLL rearrangements. Here, we report development of 
very potent and orally bioavailable small molecule inhibitors of the menin-MLL 
interaction, MI-463 and MI-503, which effectively block progression of MLL leukemia 
in vitro and in vivo, without affecting normal hematopoiesis. We also demonstrate 
efficacy of these compounds in primary leukemia samples derived from MLL leukemia 
patients. These studies provide a rationale for clinical evaluation of the menin-MLL 
inhibitors as a valuable therapeutic approach for acute leukemias associated with MLL 
rearrangements.
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Figure 1. Structure-based development of potent menin-MLL inhibitors
(A) Chemical structure and in vitro activity for MI-136. IC50 was measured by fluorescence 
polarization assay and Kd was determined by Isothermal Titration Calorimetry (ITC). (B) 
Summary of structure-activity relationship for menin-MLL inhibitors. R1, R2 and R3 
indicate substitution sites explored for modifications. Best substituents at R1, R2 and R3 
positions are shown. (C) Structures and activities of MI-463 and MI-503 menin-MLL 
inhibitors. (D) Binding isotherm from ITC for MI-503 binding to menin, demonstrating 
binding affinity (Kd) and stoichiometry (N). (E) Crystal structure of MI-503 bound to 
menin. Protein is shown in ribbon representation and key menin residues involved in 
interactions with MI-503 are shown as sticks. MI-503 is shown in stick representation with 
colors corresponding to the atom type (green: carbons, dark blue: nitrogens, yellow: sulfur, 
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light blue: fluorine). Dashed lines represent hydrogen bonds between the ligand and protein. 
See also Figure S1 and Tables S1, S2 and S3.
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Figure 2. Activity of menin-MLL inhibitors in MLL leukemia cells
(A) Co-immunoprecipitation experiment in HEK293 cells transfected with MLL-AF9 upon 
treatment with DMSO, MI-463 and MI-503. Control (cntrl) represents an untransfected 
sample. (B) Titration curves from MTT cell viability assay after 7 days of treatment with 
MI-463 and MI-503 of MLL-AF9 and Hoxa9/Meis1 (HM-2) transformed murine bone 
marrow cells (BMCs); mean ± SD, n = 4. (C) Titration curves from MTT assay performed 
for 7 days of treatment of human MLL leukemia cell lines with MI-503: MV4;11 (MLL-
AF4), MOLM-13 (MLL-AF9), KOPN-8 (MLL-ENL) and SEM (MLL-AF4) and control 
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AML cell lines without MLL translocations: HL-60, NB4 and Jurkat; mean ± SD, n = 4. (D) 
Wright-Giemsa-stained cytospins for MLL-AF9 transformed BMCs after 10 days of 
treatment with MI-503. (E) Quantification of CD11b expression in MLL-AF9 transformed 
BMCs treated for 7 days with MI-463 and MI-503 detected by flow cytometry; mean ± SD, 
n = 2. (F) Wright-Giemsa-stained cytospins for MV4;11 and MOLM-13 after 7 days of 
treatment with MI-503. (G) Apoptosis and cell death induced by MI-463 and MI-503 after 7 
days of treatment in the MLL-AF9 BMC. Quantification of Annexin V and Propidium 
Iodide (PI) staining was detected by flow cytometry; mean ± SD, n = 2. (H) Quantitative 
real-time PCR performed in MLL-AF9 BMCs after 6 days of treatment with MI-463 and 
MI-503. Expression of Hoxa9 and Meis1 was normalized to β-actin and referenced to 
DMSO-treated cells; mean ± SD, n = 2. (I) Long term viability studies with different 
concentrations of MI-503 in MV4;11 cells. Cells were treated for 10 days, followed by 10 
days of no treatment with subsequent 10 days of additional treatment. Viable cells were 
normalized to DMSO control. (J) Quantitative RT- PCR performed in MV4;11 cells upon 
treatment with MI-503 or DMSO at the end of each treatment or withdrawal phase (days 10, 
20 and 30). Expression of HOXA9 and MEIS1 was normalized to 18S rRNA and referenced 
to DMSO-treated cells. Data in I and J represent mean values for duplicates ± SD. See also 
Figure S2.
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Figure 3. Effect of menin-MLL inhibitors on gene expression in MLL-rearranged human 
leukemia cells
(A, B) Gene Set Enrichment Analysis (GSEA) of genes downregulated upon treatment with 
MI-389 in MV4;11 cells as compared with genes bound by MLL-AF4 in human SEM cells 
(Guenther et al., 2008) (A) or MLL-AF9 targets (Bernt et al., 2011) (B). (C) GSEA of genes 
upregulated by MI-389 treatment of MV4;11 cells as compared with genes underexpressed 
in primitive hematopoietic progenitor cells (Jaatinen et al., 2006). The heat maps show 
genes comprising the leading edge of the GSEA plots. Red indicates high expression, blue 
indicates low expression. Triplicate samples were used for global gene expression studies. 
NES: Normalized Enrichment Score, FDR: False Discovery Rate. (D) Quantitative RT-PCR 
performed in MV4;11 cells after 10 days of treatment with 0.6 μM of MI-503. (E) 
Quantitative RT-PCR performed in MOLM-13 cells after 6 days of treatment with MI-389 
(2 μM) or MI-503 (1 μM). Expression of genes in (D) and (E) was normalized to 18S rRNA 
and referenced to DMSO-treated cells. Data in (D) and (E) represent mean values for 
duplicates ± SD. See also Figure S3 and Table S4.
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Figure 4. Menin-MLL inhibitors block hematological tumors in vivo, increase survival and 
reduce MLL leukemia tumor burden
(A) Pharmacokinetic studies in mice performed for MI-503 (top panel, mean ± SD, n = 2) 
and MI-463 (bottom panel, mean ± SD, n = 2) demonstrating blood concentration of the 
compounds after oral (p.o.) dose of 30 mg/kg or 100 mg/kg as well as intravenous (i.v.) 
administration at 15 mg/kg. (B) In vivo inhibition of the tumor growth by MI-503 (top 
panel) and MI-463 (bottom panel) after subcutaneous injection of 1 × 107 MV4;11 cells into 
BALB/c nude mice, n = 6 per group. Mice were treated once daily with MI-503 (60 mg/kg) 
or MI-463 (35 mg/kg) via i.p. (p < 0.003 for each compound). Error bars represent SEM. (C) 
Expression of HOXA9 and MIES1 measured by qRT-PCR of RNA extracted from tumor 
samples harvested at the end point of treatment with MI-503 (day 38, top panel) or MI-463 
(day 28, bottom panel). HOXA9 and MEIS1 transcripts levels are normalized to the mean 
transcript level in tumors from the vehicle treated groups; n = 4 per group. Boxes represent 
the first and third quartiles, the line represents the median and the whiskers show the lowest 
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and the highest values. (D) Bioluminescent imaging of NSGS mice transplanted with 
MV4;11 human MLL leukemia cells expressing luciferase at the indicated days after 
initiation of treatment with MI-503 (60 mg/kg, twice daily every 12 hr, i.p.) or vehicle, n = 9 
mice per group. (E) Quantification of bioluminescence imaging in NSG mice transplanted 
with luciferase-expressing MV4;11 cells at the indicated days after initiation of treatment 
with MI-463 (45 mg/kg, twice daily, p.o.) or vehicle, n = 6–7 mice per group. Error bars 
represent SEM. (F) Bioluminescence imaging of mice from panel (E) at the last day of 
treatment (day 20). (G) Flow cytometry quantification of human CD45+ cells in blood, 
spleen and bone marrow samples harvested from NSG mice transplanted with MV4;11 cells 
after last treatment (day 20) with MI-463 or vehicle. Error bars represent SEM, n = 5–6. (H) 
Expression of HOXA9, MIES1, MEF2C and ITGAM measured by qRT-PCR of RNA 
extracted from spleen samples harvested after last treatment (day 20) with MI-463 or 
vehicle. Transcripts levels are normalized to GAPDH and referenced to the mean transcript 
level in vehicle treated group, which is set as 1 (n = 6 independent samples per group). Error 
bars represent SEM. See also Figure S4.
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Figure 5. Treatment with menin-MLL inhibitor blocks progression of MLL leukemia in vivo
(A) Kaplan-Meier survival curves of vehicle and MI-503 or MI-463 treated C57BL/6 mice 
transplanted with 1 × 105 syngeneic MLL-AF9 leukemic cells isolated from primary 
recipient mice (n = 9 mice per group). Time of treatment is indicated on each graph. P 
values were calculated using Log-rank (Mantel-Cox) test, and are p < 0.0001 for each 
compound. (B) Representative photographs of the spleen from control and MI-463 treated 
(40 mg/kg, twice daily, p.o.) MLL-AF9 leukemia mice (n = 6–7 mice per group). Treatment 
was initiated 5 days after transplantation and continued for 10 days. Samples from all mice 
were collected one day after treatment was stopped. (C) Comparison of spleen weight for the 
MLL-AF9 leukemia mice treated with vehicle (n = 6) or MI-463 (n = 7), treatment as 
described in panel (B); mean ± SEM. (D) Quantification of leukemic blasts in bone marrow 
of MLL-AF9 leukemia mice upon treatment with MI-463 or vehicle (n = 6 mice per group) 
by flow cytometry analysis. GFP (Green Fluorescent Protein) is detected as a surrogate for 
MLL-AF9 expressed from the MigR1 vector, reflecting MLL-AF9 expressing leukemic 
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blasts. Boxes represent the first and third quartiles, the line represents the median and the 
whiskers show the lowest and the highest values. (E) Representative histograms from flow 
cytometry analysis of the leukemic blasts in bone marrow samples of the MLL-AF9 mice 
treated with vehicle or MI-463. SS – side scatter. (F) Histological sections of liver 
parenchyma from control and MI-463 treated mice. (G) Wright-Giemsa-stained cytospins 
for bone marrow samples isolated from MLL-AF9 mice treated with MI-463 and vehicle 
(treatment described in B). Bone marrow cells with neutrophil-like morphology in MI-463 
treated mice are indicated by black arrows. (H) Treatment with MI-463 reduces white blood 
cell (WBC) level in the peripheral blood; mean ± SEM, n = 6. (I) Expression of Hox9, 
Meis1, Mef2c, Flt3 and Itgam measured by qRT-PCR of RNA extracted from bone marrow 
samples harvested the next day after last treatment (treatment was continued for 10 days) 
with MI-463 or vehicle. Transcripts levels are normalized to β-actin and referenced to the 
mean transcript level in vehicle treated group, which is set as 1 (n = 4 replicates per group). 
Boxes represent the first and third quartiles, the line represents the median, and the whiskers 
show the lowest and the highest values. See also Figure S5.
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Figure 6. Pharmacologic inhibition of the menin-MLL interaction does not impair normal 
hematopoiesis in mice
(A) Analysis of bone marrow (BM) cellularity after 10 days of treatment of normal 
C57BL/6 mice with MI-463 (40 mg/kg), MI-503 (70 mg/kg) or vehicle control (twice daily 
via oral gavage; n = 8–9/group, mean ± SD). ns – not significant. (B) Representative 
histograms from flow cytometry analysis of hematopoietic stem and progenitor cells: LSK 
(Lin−Sca-1+c-Kit+) and long-term repopulating cells (LT-HSC, defined as Lin−Sca-1+c-
Kit+CD48−CD150+), left panel. Right panel: quantification of LSK and LT-HSC cell 
frequency by flow cytometry (n = 8–9/group, mean +/− SD), *p<0.05, ***p<0.001 
(treatment described in panel A). (C) Representative histograms (left panel) and 
quantification (right panel) from fIow cytometry analysis of mature myeloid cells in bone 
marrow (BM) samples isolated from mice treated with vehicle, MI-463 or MI-503 (n = 8–9/
group, mean ± SD); treatment described in panel (A). (D) Representative histograms (left 
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panel) and quantification (right panel) from flow cytometry analysis of BM pro-B cell 
populations (B220+CD43hisIgMnegCD19+AA4.1+) (n = 8–9/group, mean ± SD). *p<0.05. 
(E) Expression of Hoxa9 measured by qRT-PCR of RNA extracted from LSK cells 
harvested after 10 days of treatment with MI-463, MI-503 or vehicle. Transcripts levels are 
normalized to Hprt1 and referenced to the mean transcript level in vehicle treated group, 
which is set as 1 (n = 5–6 per group), mean ± SD. (F) Analysis of bone marrow cellularity 
and mature myeloid cells after 38 days of treatment with MI-503 (60 mg/kg, once daily, i.p.) 
or vehicle in the subcutaneous MV4;11 xenograft mice (BALB/c nude); mean ± SD, n = 5–6 
per group. (G) Analysis of hematopoietic progenitor cells after 38 days of treatment with 
MI-503 (60 mg/kg, once daily, i.p., n = 5–6/group, mean ± SD). Analysis was performed in 
the subcutaneous MV4;11 xenograft mice (BALB/c nude), *p<0.05. See also Figure S6.
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Figure 7. Menin-MLL inhibitors selectively kill MLL leukemia primary patient samples
(A, B) Colony counts for methylcellulose colony forming assay performed upon 14 days of 
treatment with MI-463 and MI-503 in primary patient samples with MLL leukemia (A) and 
in AML primary patient samples without MLL translocations (B). Colony counts are 
normalized to DMSO treated samples (mean ± SD, n= 2). (C) Pictures of colonies in one 
primary sample with MLL translocation (MLL-1907, top) and one AML primary sample 
without MLL translocation (AML-7799, bottom) treated as indicated. (D) Flow cytometry 
analysis of human CD45+ cells upon 7 days of treatment of primary patient samples with 
MLL translocations (MLL-30, MLL-15) and without MLL translocations (AML-12, 
AML-10) with MI-463 or DMSO. Percentage of blasts in each sample is shown (mean ± 
SD, n = 2). (E) Histograms from flow cytometry analysis of blasts level (hCD45+ cells) 
upon treatment of primary patient samples with MI-463 and DMSO. See also Figure S7.
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